A simple model predicts freedom from biochemical recurrence after low-dose rate prostate brachytherapy alone

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 30, Issue 2, 2007, Pages 199-204

  Papagikos, Michael A ^a   Rossi, Peter J ^a   Urbanic, James J ^a   DeGuzman, Allan F ^a   McCullough, David L ^a   Clark, Peter E ^a   Lee, W Robert ^a,b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Dosimetry; I 125; Prostate brachytherapy; PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; BRACHYTHERAPY; CANCER RELAPSE; CANCER RISK; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; FOLLOW UP; FREEDOM; GLEASON SCORE; HIGH RISK POPULATION; HUMAN; LOW ENERGY RADIATION; MAJOR CLINICAL STUDY; MALE; MODEL; MULTIVARIATE ANALYSIS; PREDICTION; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; RECURRENT DISEASE; STATISTICAL SIGNIFICANCE; UNIVARIATE ANALYSIS;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BIOPSY; BRACHYTHERAPY; COHORT STUDIES; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RECURRENCE;

EID: 34147106069     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000251402.85009.af     Document Type: Article

References (22)

1. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969-974.
2. D'Amico AV, Whittington R, Malkowicz SB, et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol. 2000;18:1164-1172.
3. D'Amico AV, Schultz D, Silver B, et al. The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2001;49:679-684.
4. Rossi PJ, Clark PE, Papagikos MA, et al. Percentage of positive biopsies associated with freedom from biochemical recurrence after low-doserate prostate brachytherapy alone for clinically localized prostate cancer. Urology. 2006;67:349-353.
5. Grimm PD, Blasko JC, Sylvester JE, et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys. 2001;51:31-40.
6. Kollmeier MA, Stock RG, Stone N. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality. Int J Radiat Oncol Biol Phys. 2003;57:645-653.
7. Lee WR, deGuzman AF, McMullen KP, et al. Dosimetry and cancer control after low-dose-rate prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2005;61:52-59.
8. Papagikos MA, deGuzman AF, Rossi PJ, et al. Dosimetric quantifiers for low-dose-rate prostate brachytherapy: is V(100) superior to D(90)? Brachytherapy. 2005;4:252-258.
9. Potters L, Huang D, Calugaru E, et al. Importance of implant dosimetry for patients undergoing prostate brachytherapy. Urology. 2003;62:1073-1077.
10. Potters L, Morgenstern C, Calugaru E, et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol. 2005;173:1562-1566.
11. Stock RG, Stone NN, Dahlal M, et al. What is the optimal dose for 125I prostate implants? A dose-response analysis of biochemical control, posttreatment prostate biopsies, and long-term urinary symptoms. Brachytherapy. 2002;1:83- 89.
12. Stock RG, Stone NN. Importance of post-implant dosimetry in permanent prostate brachytherapy. Eur Urol. 2002;41:434-439.
13. Urbanic JJ, Lee WR. Update on brachytherapy in localized prostate cancer: the importance of dosimetry. Curr Opin Urol. 2006;16:157-161.
14. Blasko JC, Mate T, Sylvester JE, et al. Brachytherapy for carcinoma of the prostate: techniques, patient selection, and clinical outcomes. Semin Radiat Oncol. 2002;12:81-94.
15. Grimm PD, Blasko JC, Ragde H, et al. Does brachytherapy have a role in the treatment of prostate cancer? Hematol Oncol Clin North Am. 1996;10:653-673.
16. Nath R, Anderson LL, Luxton G, et al. Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine. Med Phys. 1995;22:209-234.
17. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys. 1997;37:1035-1041.
18. Lee WR, deGuzman AF, Bare RL, et al. Postimplant analysis of transperineal interstitial permanent prostate brachytherapy: evidence for a learning curve in the first year at a single institution. Int J Radiat Oncol Biol Phys. 2000;46:83-88.
19. Stock RG, Stone NN, Tabert A, et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys. 1998;41:101-108.
20. Kestin LL, Goldstein NS, Vicini FA, et al. Percentage of positive biopsy cores as predictor of clinical outcome in prostate cancer treated with radiotherapy. J Urol. 2002;168:1994-1999.
21. Merrick GS, Butler WM, Galbreath RW, et al. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland. Int J Radiat Oncol Biol Phys. 2002;52:664-673.
22. Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol. 1997;157:199-202.